
NYSEHealthcareMedical - Diagnostics & Research
最新数据
US$44.18
−US$0.61 · -1.36%
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
常规交易时段
US$44.18
−US$0.61 · -1.36%
盘中时间采用ET。市场数据可能有所延迟。
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
日内区间
当前US$44.18
52周区间
当前US$44.18
盘中时间采用ET。市场数据可能有所延迟。
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
日内区间
当前US$44.18
52周区间
当前US$44.18
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 20.9亿 USD | 19.78亿 USD | 19.65亿 USD | 21.42亿 USD | 22.52亿 USD |
| 销货成本 | 7.99亿 USD | 10.11亿 USD | 7.32亿 USD | 7.57亿 USD | 8.01亿 USD |
| 毛利 | 12.91亿 USD | 9.67亿 USD | 12.34亿 USD | 13.85亿 USD | 14.51亿 USD |
| 研究与开发 | 1.88亿 USD | 1.93亿 USD | 1.99亿 USD | 1.9亿 USD | 1.9亿 USD |
| 销售、一般及管理费用 | 5.84亿 USD | 5.64亿 USD | 5.79亿 USD | 6.04亿 USD | 5.84亿 USD |
| 营业费用 | 7.71亿 USD | 8.7亿 USD | 8.24亿 USD | 8.53亿 USD | 8.21亿 USD |
| 利息收入 | 6432万 USD | 6801.6万 USD | 7899.2万 USD | 3275.7万 USD | 955.5万 USD |
| 利息支出 | 3325.6万 USD | 4384.1万 USD | 5341万 USD | 5835.7万 USD | 5447.7万 USD |
| 折旧和摊销 | 1.94亿 USD | 2.03亿 USD | 2.05亿 USD | 2.08亿 USD | 2.15亿 USD |
| 营业利润 | 5.2亿 USD | 9771.1万 USD | 4.1亿 USD | 5.31亿 USD | 6.3亿 USD |
| 净利润 | 4.25亿 USD | 8359.1万 USD | 3.41亿 USD | 4.23亿 USD | 5.13亿 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$43.01
下跌空间 2.65%报告持有此股票敞口的交易所交易基金。
iShares Russell Mid-Cap ETFIWR3788.98万0.07%565.66亿 USD0.18%US$108.37-0.09%
iShares Russell 1000 Value ETFIWD2050.78万0.03%822.45亿 USD0.18%US$250.7-0.03%
First Trust Health Care AlphaDEX FundFXH1579.65万1.40%11.31亿 USD0.61%US$126.97-1.42%
iShares Russell Mid-Cap Value ETFIWS1383.72万0.09%152.18亿 USD0.23%US$162.53-0.16%
Invesco Biotechnology & Genome ETFPBE1224.39万2.97%4.12亿 USD0.59%US$92.95-1.98%
iShares Systematic Alternatives Active ETFIALT636.96万0.09%73.58亿 USD0.99%US$29.9428-0.26%
iShares Russell 1000 ETFIWB635.83万0.01%496.25亿 USD0.15%US$423.69-0.12%
iShares U.S. Healthcare ETFIYH583.09万0.15%39.65亿 USD0.37%US$69.84-2.05%
iShares Russell Mid-Cap ETFIWR
iShares Russell 1000 Value ETFIWD
First Trust Health Care AlphaDEX FundFXH
iShares Russell Mid-Cap Value ETFIWS
Invesco Biotechnology & Genome ETFPBE
iShares Systematic Alternatives Active ETFIALT
iShares Russell 1000 ETFIWB
iShares U.S. Healthcare ETFIYHAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。